×
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
LON:NFX

Nuformix (NFX) Share Forecast, Price & News

GBX 0.86
+0.05 (+6.17%)
(As of 05/27/2022 12:00 AM ET)
Add
Compare
Today's Range
0.76
0.95
50-Day Range
0.78
1.05
52-Week Range
0.75
2.40
Volume
4.43 million shs
Average Volume
4.11 million shs
Market Capitalization
£6.10 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive NFX News and Ratings via Email

Sign-up to receive the latest news and ratings for Nuformix and its competitors with MarketBeat's FREE daily newsletter.

Nuformix logo

About Nuformix

Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. Its lead programs include NXP001, which is in Phase 1-ready stage for oncology supportive care; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. The company is also developing NXP004, which is in the research Phase for treating oncology. It also has an option agreement with Oxilio Ltd. for developing and exploiting NXP001 for the treatment of cancer. Nuformix plc was founded in 2008 and is based in London, the United Kingdom.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
5
Year Founded
N/A

Sales & Book Value

Annual Sales
£50 thousand
Cash Flow
GBX 0.20 per share
Book Value
GBX 0.90 per share

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
£6.10 million
Optionable
Optionable

Company Calendar

Last Earnings
7/22/2020
Today
5/28/2022
Next Earnings (Estimated)
7/20/2022

MarketRank

Overall MarketRank

1.00 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -













Nuformix (LON:NFX) Frequently Asked Questions

When is Nuformix's next earnings date?

Nuformix is scheduled to release its next quarterly earnings announcement on Wednesday, July 20th 2022.
View our earnings forecast for Nuformix
.

How were Nuformix's earnings last quarter?

Nuformix plc (LON:NFX) posted its earnings results on Wednesday, July, 22nd. The company reported ($0.16) EPS for the quarter.
View Nuformix's earnings history
.

Who are Nuformix's key executives?
Nuformix's management team includes the following people:
  • Dr. Joanne M. Holland, Consultant (Age 47, Pay $97k)
  • Dr. Alastair James Riddell M.D., M.Sc., MBChB, MFPM, MRCGP, MSc, Ph.D., Exec. Chairman (Age 73)
  • Mr. Benjamin Harber, Company Sec.
What other stocks do shareholders of Nuformix own?
What is Nuformix's stock symbol?

Nuformix trades on the London Stock Exchange (LON) under the ticker symbol "NFX."

How do I buy shares of Nuformix?

Shares of NFX and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Nuformix's stock price today?

One share of NFX stock can currently be purchased for approximately GBX 0.86.

How much money does Nuformix make?

Nuformix has a market capitalization of £6.10 million and generates £50 thousand in revenue each year.

How many employees does Nuformix have?

Nuformix employs 5 workers across the globe.

What is Nuformix's official website?

The official website for Nuformix is www.levrett.com.

How can I contact Nuformix?

Nuformix's mailing address is Ste 31 Second Fl, 107 Cheapside, LONDON, EC2V 6DN, United Kingdom. The company can be reached via phone at 44 1223 423 667.

This page was last updated on 5/28/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.